CLINICAL USE OF CYSTINE SUPERSATURATION MEASUREMENTS
- 1 November 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (5) , 1481-1485
- https://doi.org/10.1016/s0022-5347(05)67011-5
Abstract
We measured the concentration and solubility of cystine in urine from patients with cystinuria or calcium stones and from normal subjects to determine whether urine cystine supersaturation can be calculated from a standard nomogram of solubility versus pH or needs to be measured directly. We also evaluated whether increasing pH of the 24-hour collection recovered enough crystallized cystine to increase cystine supersaturation. Cystine concentration, pH and usual stone risk factors were measured on 50 ml. aliquots of 24-hour collections from 24 patients with cystinuria, 22 calcium stone formers and 15 normal subjects. After 48 hours of incubation with sodium bicarbonate, a second aliquot was taken from the 24-hour collection for cystine concentration. The original urine at its ambient pH was incubated with an excess of cystine crystals for 24, 48, 72 or 96 hours at 37C to determine solubility and kinetics of equilibration. Cystine solubility varied so widely at any pH range that no predictive nomogram could be relied on for calculating supersaturation. Addition of sodium bicarbonate to the 24-hour urine significantly increased cystine concentration. Urine from stone formers had higher cystine solubility than urine from normal subjects. Clinical management of cystinuria can be improved by direct measurement of cystine solubility because it varies widely at any given pH. Increasing 24-hour collection pH with sodium bicarbonate additionally improves accuracy of supersaturation measurement by recovering crystallized cystine.Keywords
This publication has 11 references indexed in Scilit:
- A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interferenceClinica Chimica Acta; International Journal of Clinical Chemistry, 1999
- Linkage of type II and type III cystinuria to 19q13.1: Codominant inheritance of two cystinuric alleles at 19q13.1 produces an extreme stone-forming phenotypeAmerican Journal of Medical Genetics, 1999
- Mutations in the Genomic Deoxyribonucleic Acid for SLC3A1 in Patients with CystinuriaJournal of Clinical Endocrinology & Metabolism, 1998
- Cystinuria subtype and the risk of nephrolithiasisKidney International, 1998
- 335-base deletion in the mRNA coding for a dibasic amino acid transporter-like protein (SLC3A1) isolated from a patient with cystinuriaHuman Mutation, 1998
- Recent Advances in the Biochemical and Molecular Biological Basis of CystinuriaJournal of Urology, 1996
- Clinical course and cystine stone formation during tiopronin treatmentUrological Research, 1995
- Assessment of Cystine Solubility in Urine and of Heterogeneous NucleationJournal of Urology, 1983
- Nomograms for the estimation of the saturation of urine with calcium oxalate, calcium phosphate, magnesium ammonium phosphate, uric acid, sodium acid urate, ammonium acid urate and cystineClinica Chimica Acta; International Journal of Clinical Chemistry, 1976
- STUDIES ON THE TREATMENT OF CYSTINURIA1British Journal of Urology, 1955